Clinical trials: Depression NOS
Suicide, Mental Health Disorder
A Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death among youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT05920252
- Testing
- Vira, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Ksana Health
Major Depressive Disorder
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
- Trial name
- NCT03833206
- Testing
- PDC-1421 Capsule
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- BioLite, Inc.
Major Depression
Safety and Pharmacology Study of BMS-866949
The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable
- Trial name
- NCT01124344
- Testing
- BMS-866949
- Where
- Sweden
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Postpartum Depression
A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the…
- Trial name
- NCT02978326
- Testing
- SAGE-217 15/20 mg Oral Solution, SAGE 217 30 mg Capsules
- Where
- 27 sites in United States
- Volunteers
- 276 people
- Sponsor
- Biogen
Depression
Vortioxetine to Prevent Return of Symptoms in Children With Depression
The purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.
- Trial name
- NCT05014919
- Testing
- Vortioxetine
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 35 people
- Sponsor
- H. Lundbeck A/S
Depression
Single Ascending Dose Study of NH102 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as single oral dose at escalating dose levels in healthy participants.
- Trial name
- NCT05015192
- Testing
- NH102
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Unipolar Depression
Transcranial Direct Current Stimulation for Depression
This study will test the efficacy of transcranial direct current stimulation (tDCS) combined with mindfulness, remotely-delivered using a telemedicine protocol in 25 adults with unipolar depression.
- Trial name
- NCT07042217
- Testing
- transcranial direct current stimulation (tDCS) and mindfulness instruction
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Anxiety
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of…
- Trial name
- NCT02411123
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- AltheaDx
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
MDD, Anxiety Disorders
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression coexisting with generalized anxiety disorder.
- Trial name
- RECONNECT (NCT04220996)
- Testing
- Vortioxetine
- Where
- 21 sites in Estonia, France and 4 more
- Volunteers
- 100 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder.
- Trial name
- NCT00081380
- Testing
- Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
- Where
- 94 sites in United States, Canada
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Depression, Anxiety, IBS - Irritable Bowel Syndrome
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this…
- Trial name
- NCT04905524
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Viome
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- ORION (NCT00252356)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- Sanofi
Non-psychotic Unipolar Major Depression
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial
A non interventional, descriptive, longitudinal cohort study is designed, trying to obtain local data about the prevalence of non remitted depressed patients after an antidepressant treatment, and to get information about…
- Trial name
- PANTHER (NCT01887639)
- Where
- 8 sites in Argentina
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Treatment Resistant Depression, Depressive Disorder
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for…
- Trial name
- NCT01801319
- Testing
- Libra Deep Brain Stimulation System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Chronic Low-back Pain, Anxiety
EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain
The aim of this randomized controlled trial (RCT) is to assess outcomes for virtual reality therapy (including pain intensity, pain interference, anxiety, depression, physical function, sleep, behavioral skills development…
- Conditions
- Chronic Low-back Pain, Anxiety, Depression
- Trial name
- AVR_HEOR (NCT05263037)
- Testing
- EaseVRx
- Where
- United States
- Volunteers
- 1,093 people
- Sponsor
- AppliedVR Inc.
Depression
To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets
To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.
- Trial name
- NCT00913419
- Testing
- Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories, Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Treatment Resistant Depressive Disorder
Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression
The habenula (Hb) is an ancient structure, located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03667872
- Testing
- Bilateral implantation of DBS system to Habeluna
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Pins Medical Co., Ltd